PARP3: A Potential Drug Target and Biomarker (G10039)

Target Name: PARP3

NCBI ID: G10039

PARP3

PARP3: A Potential Drug Target and Biomarker

Parapleukemia (PL) is a rare hematological disorder that is characterized by the production of a single paragraph in the blood cells that are responsible for maintaining the normal number of chromosomes. PARP3, which stands for poly (ADP-ribose) polymerase 3, is a gene that has been identified as a potential drug target and biomarker for PL.

PL is a genetic disorder that is inherited from an individual's parents, and it is characterized by the production of a single paragraph in the blood cells that are responsible for maintaining the normal number of chromosomes. This leads to the characteristic symptoms and characteristics of PL, such as anemia, fatigue, and bone marrow failure.

PARP3 is a gene that has been identified as a potential drug target and biomarker for PL. The PARP3 gene is a member of the PARP family, which includes genes that are involved in the repair of DNA damage. PARP3 is responsible for the production of PARP, which is a protein that plays a critical role in the repair of DNA damage.

Studies have shown that PL is caused by a deficiency in the PARP3 gene, which leads to a lack of effective DNA repair. This can result in the accumulation of DNA damage in the cells, leading to the development of PL symptoms.

PARP3 has also been shown to be involved in the development of other types of cancer, including breast and ovarian cancer. This suggests that it may be a useful biomarker for these types of cancer, as well as PL.

In addition to its potential as a drug target and biomarker, PARP3 is also of interest as a potential therapeutic target for PL. Treatments for PL typically involve chemotherapy, which can cause significant side effects, such as fatigue, anemia, and neurotoxicity. By targeting PARP3, researchers may be able to develop more effective and less toxic treatments for PL.

Overall, PARP3 is a gene that has the potential to be a drug target and biomarker for PL. Further research is needed to fully understand its role in the development and treatment of PL.

Protein Name: Poly(ADP-ribose) Polymerase Family Member 3

Functions: Mono-ADP-ribosyltransferase that mediates mono-ADP-ribosylation of target proteins and plays a key role in the response to DNA damage (PubMed:16924674, PubMed:20064938, PubMed:21211721, PubMed:21270334, PubMed:25043379, PubMed:24598253, PubMed:28447610, PubMed:19354255, PubMed:23742272). Mediates mono-ADP-ribosylation of glutamate, aspartate or lysine residues on target proteins (PubMed:20064938, PubMed:25043379). In contrast to PARP1 and PARP2, it is not able to mediate poly-ADP-ribosylation (PubMed:25043379). Involved in DNA repair by mediating mono-ADP-ribosylation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism, such as histone H2B, XRCC5 and XRCC6 (PubMed:16924674, PubMed:24598253). ADP-ribosylation follows DNA damage and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks (PubMed:16924674, PubMed:21211721, PubMed:21270334). Involved in single-strand break repair by catalyzing mono-ADP-ribosylation of histone H2B on 'Glu-2' (H2BE2ADPr) of nucleosomes containing nicked DNA (PubMed:27530147). Cooperates with the XRCC5-XRCC6 (Ku80-Ku70) heterodimer to limit end-resection thereby promoting accurate NHEJ (PubMed:24598253). Suppresses G-quadruplex (G4) structures in response to DNA damage (PubMed:28447610). Associates with a number of DNA repair factors and is involved in the response to exogenous and endogenous DNA strand breaks (PubMed:16924674, PubMed:21211721, PubMed:21270334). Together with APLF, promotes the retention of the LIG4-XRCC4 complex on chromatin and accelerate DNA ligation during non-homologous end-joining (NHEJ) (PubMed:21211721). May link the DNA damage surveillance network to the mitotic fidelity checkpoint (PubMed:16924674). Acts as a negative regulator of immunoglobulin class switch recombination, probably by controlling the level of AICDA /AID on the chromatin (By similarity). In addition to proteins, also able to ADP-ribosylate DNA: mediates DNA mono-ADP-ribosylation of DNA strand break termini via covalent addition of a single ADP-ribose moiety to a 5'- or 3'-terminal phosphate residues in DNA containing multiple strand breaks (PubMed:29361132, PubMed:29520010)

The "PARP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PARP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets